BSN: Targeting Cyclic AMP Signalling to Combat Cardiovascular Diseases

Home

News

Calendar

Top 200 Orgs

Top Orgs by Specialty

People, Speakers

About Us

My Profile

How We Rank

What's My Rank?
      What's My Popularity Score?
      In My Orgs?
      In My Specialities?
      In My Geography?
      In My Age?

My Mentors, Collaborators,
Associates, Peers, Buddies

Keep Me Up To Date
Specialty, Keyword,
Geography

People Making News

Latest Research From
Meetings

Recent Postings

People of Consequence (74510)

1. Peter Kowey
Lankenau Hospital
2. Lawrence W. Bassett
University of California
3. Robert S Kerbel
University of Toronto
4. Yehuda Shoenfeld
Sheba Medical Center
5. Paul Weiss
Gala Biotech business unit of Cardinal Health

Orgs of Consequence (21209)

1. University of California
2. Harvard University
3. The Mayo Clinic
4. National Institutes of Health
5. University of California, San Francisco

Terms of Consequence

1. Cells
2. Cancer
3. Genetics
4. Molecular
5. Proteins

Targeting Cyclic AMP Signalling to Combat Cardiovascular Diseases

Charles Darwin House

London, UK
http://www.biochemistry.org/Conferences/AllConferences/tabid/379/View/Programme/Page/2/MeetingNo/HT007/Default.aspx

Targeting Cyclic AMP Signalling to Combat Cardiovascular Diseases
Biochemical Society
http://www.biochemistry.org/Conferences/AllConferences/tabid/379/View/Programme/Page/2/MeetingNo/HT007/Default.aspx
Charles Darwin House
London
UK

Schedule of Presentations:

Monday, December 9, 2013
08:30:00	Registration with tea and coffee
09:50:00	Session 1: Cyclic AMP and Cardiovascular Disease - Classical Signalling	Stephen Yarwood, Tim Palmer
10:00:00	Targeting Mitochondria to Restore Impaired Metabolic Adaptation to Exercise	Jane Reusch
10:35:00	Activation of both protein kinase A and Epac is necessary for cardioprotective effect induced by a cell-permeable cyclic AMP	Igor Khaliulin
10:50:00	Persistent PKA signalling at the outer mitochondrial membrane of cardiac myocytes.	Konstantinos Lefkimmiatis
11:05:00	Coffee/tea break
11:30:00	Dynamics of receptor mediated cAMP signalling revealed by FRET microscopy	Moritz Bünemann
12:00:00	TGR5 signaling inhibits macrophage activation and atherosclerosis	Thijs Pols
12:40:00	Disruption of HSP20-PDE4D5 interaction protects against cardiac hypertrophy	Tamara Martin
12:55:00	EPAC1 signalling induces morphological change and cytoskeletal reorganisation
13:10:00	cAMP signalling modulates platelet contractile machinery by targeting the RhoA-Rho Kinase-MLC phosphatase signalling pathway
13:35:00	Lunch and informal discussions
14:30:00	PDEs as Signalling Gatekeepers in Multiple Vascular Endothelial Cell Compartments	Don Maurice
15:00:00	Cavin-1: A new SOCS3-interacting regulator of cytokine signalling?
15:20:00	Phosphodiesterases regulate cAMP pools at individual macromolecular complexes in cardiac myocytes
15:35:00	Inhibition of platelets by cAMP requires lipid raft targeting of protein kinase A type I by the A-kinase anchoring protein Moesin
15:50:00	Coffee and tea break
16:20:00	Cyclic AMP Signalling during Cardiac Remodelling
16:55:00	The cAMP-binding Popdc proteins have a redundant function in the heart	Thomas Brand
17:10:00	Tapping the Translation Potential of cAMP-Signaling: Molecular Basis for Selectivity in cAMP Agonism and Antagonism as Revealed by NMR	Giuseppe Melacini
17:25:00	Poster session and drinks reception

BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.